Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma

Lenka Sinik, Katherine A. Minson, John J. Tentler, Jacqueline Carrico, Stacey M. Bagby, William A. Robinson, Rotem Kami, Tal Burstyn-Cohen, S Gail Eckhardt, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Molecularly-targeted agents have improved outcomes for a subset of patients with BRAF-mutated melanoma, but treatment of resistant and BRAF wild-type tumors remains a challenge. The MERTK receptor tyrosine kinase is aberrantly expressed in melanoma and can contribute to oncogenic phenotypes. Here we report the effect of treatment with a MERTK-selective small molecule inhibitor, UNC2025, in preclinical models of melanoma. In melanoma cell lines, treatment with UNC2025 potently inhibited phosphorylation of MERTK and downstream signaling, induced cell death, and decreased colony formation. In patient-derived melanoma xenograft models, treatment with UNC2025 blocked or significantly reduced tumor growth. Importantly, UNC2025 had similar biochemical and functional effects in both BRAF-mutated and BRAF wild-type models and irrespective of NRAS mutational status, implicating MERTK inhibition as a potential therapeutic strategy in tumors that are not amenable to BRAF-targeting and for which there are limited treatment options. In BRAF-mutated cell lines, combined treatment with UNC2025 and the BRAF inhibitor vemurafenib provided effective inhibition of oncogenic signaling through ERK, AKT, and STAT6, increased induction of cell death, and decreased colony-forming potential. Similarly, in NRAS-mutated cell lines, addition of UNC2025 to cobimetinib therapy increased cell death and decreased colony-forming potential. In a BRAF-mutated patient-derived xenograft, treatment with combined UNC2025 and vemurafenib was well-tolerated and significantly decreased tumor growth compared with vemurafenib alone. These data support the use of UNC2025 for treatment of melanoma, irrespective of BRAF or NRAS mutational status, and suggest a role for MERTK and targeted combination therapy in BRAF and NRAS-mutated melanoma.

Original languageEnglish (US)
Pages (from-to)278-288
Number of pages11
JournalMolecular cancer therapeutics
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Melanoma
Growth
Neoplasms
Therapeutics
Cell Death
Heterografts
Cell Line
UNC2025
Receptor Protein-Tyrosine Kinases
Phosphorylation
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sinik, L., Minson, K. A., Tentler, J. J., Carrico, J., Bagby, S. M., Robinson, W. A., ... Graham, D. K. (2019). Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. Molecular cancer therapeutics, 18(2), 278-288. https://doi.org/10.1158/1535-7163.MCT-18-0456

Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. / Sinik, Lenka; Minson, Katherine A.; Tentler, John J.; Carrico, Jacqueline; Bagby, Stacey M.; Robinson, William A.; Kami, Rotem; Burstyn-Cohen, Tal; Eckhardt, S Gail; Wang, Xiaodong; Frye, Stephen V.; Shelton Earp, H.; DeRyckere, Deborah; Graham, Douglas K.

In: Molecular cancer therapeutics, Vol. 18, No. 2, 01.02.2019, p. 278-288.

Research output: Contribution to journalArticle

Sinik, L, Minson, KA, Tentler, JJ, Carrico, J, Bagby, SM, Robinson, WA, Kami, R, Burstyn-Cohen, T, Eckhardt, SG, Wang, X, Frye, SV, Shelton Earp, H, DeRyckere, D & Graham, DK 2019, 'Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma', Molecular cancer therapeutics, vol. 18, no. 2, pp. 278-288. https://doi.org/10.1158/1535-7163.MCT-18-0456
Sinik, Lenka ; Minson, Katherine A. ; Tentler, John J. ; Carrico, Jacqueline ; Bagby, Stacey M. ; Robinson, William A. ; Kami, Rotem ; Burstyn-Cohen, Tal ; Eckhardt, S Gail ; Wang, Xiaodong ; Frye, Stephen V. ; Shelton Earp, H. ; DeRyckere, Deborah ; Graham, Douglas K. / Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. In: Molecular cancer therapeutics. 2019 ; Vol. 18, No. 2. pp. 278-288.
@article{2b9d60b93fff473ca2af3180ba41e337,
title = "Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma",
abstract = "Molecularly-targeted agents have improved outcomes for a subset of patients with BRAF-mutated melanoma, but treatment of resistant and BRAF wild-type tumors remains a challenge. The MERTK receptor tyrosine kinase is aberrantly expressed in melanoma and can contribute to oncogenic phenotypes. Here we report the effect of treatment with a MERTK-selective small molecule inhibitor, UNC2025, in preclinical models of melanoma. In melanoma cell lines, treatment with UNC2025 potently inhibited phosphorylation of MERTK and downstream signaling, induced cell death, and decreased colony formation. In patient-derived melanoma xenograft models, treatment with UNC2025 blocked or significantly reduced tumor growth. Importantly, UNC2025 had similar biochemical and functional effects in both BRAF-mutated and BRAF wild-type models and irrespective of NRAS mutational status, implicating MERTK inhibition as a potential therapeutic strategy in tumors that are not amenable to BRAF-targeting and for which there are limited treatment options. In BRAF-mutated cell lines, combined treatment with UNC2025 and the BRAF inhibitor vemurafenib provided effective inhibition of oncogenic signaling through ERK, AKT, and STAT6, increased induction of cell death, and decreased colony-forming potential. Similarly, in NRAS-mutated cell lines, addition of UNC2025 to cobimetinib therapy increased cell death and decreased colony-forming potential. In a BRAF-mutated patient-derived xenograft, treatment with combined UNC2025 and vemurafenib was well-tolerated and significantly decreased tumor growth compared with vemurafenib alone. These data support the use of UNC2025 for treatment of melanoma, irrespective of BRAF or NRAS mutational status, and suggest a role for MERTK and targeted combination therapy in BRAF and NRAS-mutated melanoma.",
author = "Lenka Sinik and Minson, {Katherine A.} and Tentler, {John J.} and Jacqueline Carrico and Bagby, {Stacey M.} and Robinson, {William A.} and Rotem Kami and Tal Burstyn-Cohen and Eckhardt, {S Gail} and Xiaodong Wang and Frye, {Stephen V.} and {Shelton Earp}, H. and Deborah DeRyckere and Graham, {Douglas K.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-18-0456",
language = "English (US)",
volume = "18",
pages = "278--288",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma

AU - Sinik, Lenka

AU - Minson, Katherine A.

AU - Tentler, John J.

AU - Carrico, Jacqueline

AU - Bagby, Stacey M.

AU - Robinson, William A.

AU - Kami, Rotem

AU - Burstyn-Cohen, Tal

AU - Eckhardt, S Gail

AU - Wang, Xiaodong

AU - Frye, Stephen V.

AU - Shelton Earp, H.

AU - DeRyckere, Deborah

AU - Graham, Douglas K.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Molecularly-targeted agents have improved outcomes for a subset of patients with BRAF-mutated melanoma, but treatment of resistant and BRAF wild-type tumors remains a challenge. The MERTK receptor tyrosine kinase is aberrantly expressed in melanoma and can contribute to oncogenic phenotypes. Here we report the effect of treatment with a MERTK-selective small molecule inhibitor, UNC2025, in preclinical models of melanoma. In melanoma cell lines, treatment with UNC2025 potently inhibited phosphorylation of MERTK and downstream signaling, induced cell death, and decreased colony formation. In patient-derived melanoma xenograft models, treatment with UNC2025 blocked or significantly reduced tumor growth. Importantly, UNC2025 had similar biochemical and functional effects in both BRAF-mutated and BRAF wild-type models and irrespective of NRAS mutational status, implicating MERTK inhibition as a potential therapeutic strategy in tumors that are not amenable to BRAF-targeting and for which there are limited treatment options. In BRAF-mutated cell lines, combined treatment with UNC2025 and the BRAF inhibitor vemurafenib provided effective inhibition of oncogenic signaling through ERK, AKT, and STAT6, increased induction of cell death, and decreased colony-forming potential. Similarly, in NRAS-mutated cell lines, addition of UNC2025 to cobimetinib therapy increased cell death and decreased colony-forming potential. In a BRAF-mutated patient-derived xenograft, treatment with combined UNC2025 and vemurafenib was well-tolerated and significantly decreased tumor growth compared with vemurafenib alone. These data support the use of UNC2025 for treatment of melanoma, irrespective of BRAF or NRAS mutational status, and suggest a role for MERTK and targeted combination therapy in BRAF and NRAS-mutated melanoma.

AB - Molecularly-targeted agents have improved outcomes for a subset of patients with BRAF-mutated melanoma, but treatment of resistant and BRAF wild-type tumors remains a challenge. The MERTK receptor tyrosine kinase is aberrantly expressed in melanoma and can contribute to oncogenic phenotypes. Here we report the effect of treatment with a MERTK-selective small molecule inhibitor, UNC2025, in preclinical models of melanoma. In melanoma cell lines, treatment with UNC2025 potently inhibited phosphorylation of MERTK and downstream signaling, induced cell death, and decreased colony formation. In patient-derived melanoma xenograft models, treatment with UNC2025 blocked or significantly reduced tumor growth. Importantly, UNC2025 had similar biochemical and functional effects in both BRAF-mutated and BRAF wild-type models and irrespective of NRAS mutational status, implicating MERTK inhibition as a potential therapeutic strategy in tumors that are not amenable to BRAF-targeting and for which there are limited treatment options. In BRAF-mutated cell lines, combined treatment with UNC2025 and the BRAF inhibitor vemurafenib provided effective inhibition of oncogenic signaling through ERK, AKT, and STAT6, increased induction of cell death, and decreased colony-forming potential. Similarly, in NRAS-mutated cell lines, addition of UNC2025 to cobimetinib therapy increased cell death and decreased colony-forming potential. In a BRAF-mutated patient-derived xenograft, treatment with combined UNC2025 and vemurafenib was well-tolerated and significantly decreased tumor growth compared with vemurafenib alone. These data support the use of UNC2025 for treatment of melanoma, irrespective of BRAF or NRAS mutational status, and suggest a role for MERTK and targeted combination therapy in BRAF and NRAS-mutated melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85061027663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061027663&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-18-0456

DO - 10.1158/1535-7163.MCT-18-0456

M3 - Article

VL - 18

SP - 278

EP - 288

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -